|
Panacos Pharmaceuticals, Incorporation - Comparative Business Analysis Snapshot
Business Description
Panacos Pharmaceuticals, Incorporation. The Group's principal activity is the discovery, development and commercialization of small molecule oral drugs for the treatment of HIV and other major human viral diseases. PA-457, its lead product candidate, is an oral HIV drug currently in Phase 2 clinical trials. PA-457 is a drug called Maturation Inhibitors discovered by its scientists and their academic collaborators. It has anti-infective drug candidates in pipeline for major markets with significant, unmet medical needs. The Group is a development stage company.
Competitor Analysis
This analysis compares Panacos Pharmaceuticals, Incorporation with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
